go
go
print
send friend


THE ESICM COLLABORATIVE NETWORK: GENOSEPT

GENOSEPT: GENETICS OF SEPSIS IN EUROPE

 

It is hypothesized that the fatal outcome following treatment for severe sepsis is, in part, genetically determined. This hypothesis is based on preliminary data developed by several groups from studies of small, relatively homogeneous populations. GenOSept will test this hypothesis through three phases:

 

  • A genetic epidemiologic study of genetic predisposition to sepsis related mortality and morbidity in European intensive care units;

 

  • This unique European dataset on the effect of genetic variation on sepsis outcomes will help to explain variation in response to new treatments for sepsis, will deliver data on gender related mortality and morbidity;

 

  • Harmonization of standards for European high throughput genotyping and quality control by co-ordinating three major European genotyping centres (Wellcome Trust Centre for Human Genetics - Oxford, Cochin Institute - Paris, Helmholtz Zentrum Munchen - Munich).

      

 

The project is in its final year and continues to recruit patients. Genotyping is also well under way.

 

 

MORE INFORMATION

More information on the project, its consortium, national coordinators, as well as annual reports can be found on www.genosept.eu

  

This project is supported by the ECCRN of the ESICM.

 

GenOSept  benefits from a grant of the European Union 6th Framework-programme of RTD.